{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:28:06Z","timestamp":1792639686035,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cotadutide is a dual glucagon-like peptide 1 and glucagon receptor agonist under development for the treatment of non-alcoholic steatohepatitis and type 2 diabetes mellitus (T2DM) and chronic kidney disease. Non-alcoholic steatohepatitis is a complex disease with no approved pharmacotherapies, arising from an underlying state of systemic metabolic dysfunction in association with T2DM and obesity. Cotadutide has been shown to improve glycaemic control, body weight, lipids, liver fat, inflammation and fibrosis. We conducted a two-part, randomized phase 2a trial in men and women with overweight or obesity diagnosed with T2DM to evaluate the efficacy and safety of cotadutide compared with placebo and liraglutide. The primary endpoints were change from baseline to day 28 of treatment in postprandial hepatic glycogen (part A) and to day 35 of treatment in fasting hepatic glycogen (part B) with cotadutide versus placebo. Secondary endpoints in part B were changes in fasting hepatic glycogen with cotadutide versus the mono glucagon-like peptide 1 receptor agonist, liraglutide, and change in hepatic fat fraction. The trial met its primary endpoint. We showed that cotadutide promotes greater reductions in liver glycogen and fat compared with placebo and liraglutide. Safety and tolerability findings with cotadutide were comparable to those of previous reports. Thus, this work provides evidence of additional benefits of cotadutide that could be attributed to glucagon receptor engagement. Our results suggest that cotadutide acts on the glucagon receptor in the human liver to promote glycogenolysis and improve the metabolic health of the liver. ClinicalTrials.gov registration: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03555994\">NCT03555994<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s42255-023-00938-0","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T11:02:14Z","timestamp":1702033334000},"page":"2086-2093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2706-2669","authenticated-orcid":false,"given":"Victoria E. R.","family":"Parker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmundo","family":"Erazo-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Havekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2672-0415","authenticated-orcid":false,"given":"Esther","family":"Phielix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"de Ligt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0666-2147","authenticated-orcid":false,"given":"Kay H. M.","family":"Roumans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Mevenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folke","family":"Sjoberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7795-584X","authenticated-orcid":false,"given":"Vera B.","family":"Schrauwen-Hinderling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-2054","authenticated-orcid":false,"given":"Edvin","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Esterline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5954-3497","authenticated-orcid":false,"given":"Lars","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-1886","authenticated-orcid":false,"given":"Philip","family":"Ambery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7660-8467","authenticated-orcid":false,"given":"Lutz","family":"Jermutus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-847X","authenticated-orcid":false,"given":"Patrick","family":"Schrauwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"938_CR1","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.12735","volume":"18","author":"SJ Henderson","year":"2016","unstructured":"Henderson, S. J. et al. Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 18, 1176\u20131190 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"938_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000475737","volume":"32","author":"N Khajavi","year":"2017","unstructured":"Khajavi, N., Biebermann, H., Tsch\u00f6p, M. & DiMarchi, R. Treatment of diabetes and obesity by rationally designed peptide agonists functioning at multiple metabolic receptors. Endocr. Dev. 32, 165\u2013182 (2017).","journal-title":"Endocr. Dev."},{"key":"938_CR3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2337\/db12-0797","volume":"62","author":"TM Tan","year":"2013","unstructured":"Tan, T. M. et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62, 1131\u20131138 (2013).","journal-title":"Diabetes"},{"key":"938_CR4","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","volume":"391","author":"P Ambery","year":"2018","unstructured":"Ambery, P. et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 391, 2607\u20132618 (2018).","journal-title":"Lancet"},{"key":"938_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","volume":"2","author":"ML Boland","year":"2020","unstructured":"Boland, M. L. et al. Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis. Nat. Metab. 2, 413\u2013431 (2020).","journal-title":"Nat. Metab."},{"key":"938_CR6","doi-asserted-by":"publisher","first-page":"dgz047","DOI":"10.1210\/clinem\/dgz047","volume":"105","author":"VER Parker","year":"2020","unstructured":"Parker, V. E. R. et al. Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist. J. Clin. Endocrinol. Metab. 105, dgz047 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"938_CR7","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","volume":"44","author":"R Nahra","year":"2021","unstructured":"Nahra, R. et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care 44, 1433\u20131442 (2021).","journal-title":"Diabetes Care"},{"key":"938_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2337\/db18-78-OR","volume":"67","author":"M Jain","year":"2018","unstructured":"Jain, M. et al. MEDI0382, a GLP\/glucagon receptor dual agonist, significantly reduces hepatic fat content in subjects with type 2 diabetes mellitus.Diabetes 67, 78\u2013OR (2018).","journal-title":"Diabetes"},{"key":"938_CR9","unstructured":"GLP1R. The Human Protein Atlas https:\/\/www.proteinatlas.org\/ENSG00000112164-GLP1R\/tissue"},{"key":"938_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bbacli.2016.02.001","volume":"5","author":"MM Adeva-Andany","year":"2016","unstructured":"Adeva-Andany, M. M., Gonz\u00e1lez-Luc\u00e1n, M., Donapetry-Garc\u00eda, C., Fern\u00e1ndez-Fern\u00e1ndez, C. & Ameneiros-Rodr\u00edguez, E. Glycogen metabolism in humans. BBA Clin. 5, 85\u2013100 (2016).","journal-title":"BBA Clin."},{"key":"938_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15684-0","volume":"11","author":"KHM Roumans","year":"2020","unstructured":"Roumans, K. H. M. et al. Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance. Nat. Commun. 11, 1891 (2020).","journal-title":"Nat. Commun."},{"key":"938_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1172\/JCI118803","volume":"98","author":"BR Landau","year":"1996","unstructured":"Landau, B. R. et al. Contributions of gluconeogenesis to glucose production in the fasted state. J. Clin. Invest. 98, 378\u2013385 (1996).","journal-title":"J. Clin. Invest."},{"key":"938_CR13","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.2337\/db15-0640","volume":"64","author":"ST Chung","year":"2015","unstructured":"Chung, S. T., Chacko, S. K., Sunehag, A. L. & Haymond, M. W. Measurements of gluconeogenesis and glycogenolysis: a methodological review. Diabetes 64, 3996\u20134010 (2015).","journal-title":"Diabetes"},{"key":"938_CR14","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.2337\/diabetes.53.12.3048","volume":"53","author":"M Krssak","year":"2004","unstructured":"Krssak, M. et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53, 3048\u20133056 (2004).","journal-title":"Diabetes"},{"key":"938_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1126\/science.1948033","volume":"254","author":"DL Rothman","year":"1991","unstructured":"Rothman, D. L., Magnusson, I., Katz, L. D., Shulman, R. G. & Shulman, G. I. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 254, 573\u2013576 (1991).","journal-title":"Science"}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-023-00938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-023-00938-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-023-00938-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:06:25Z","timestamp":1703030785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-023-00938-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1038\/s42255-023-00938-0","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by AstraZeneca. V.B.S.-H. was supported by a European Research Council starting grant (no. 759161, MRS in Diabetes). Medical writing support was provided by C. Foster, Oxford PharmaGenesis, which was funded by AstraZeneca. V.E.R.P., D.R., Y.-T.C., R.E., L.H., P.A. and L. Jermutus are employees and stockholders of AstraZeneca. E.J. is an employee of Antaros Medical. L. Johansson is an employee and stockholder of Antaros Medical. P.S. has received institutional research funding from AstraZeneca. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}